Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 498

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 498
---
 acquisition of Kadimastem been completed as of the dates indicated. The companies may have performed differently had they been combined during the periods presented. Specifically, the unaudited pro forma condensed combined financial information does not reflect any cost savings, operating synergies, revenue enhancements or restructuring costs that the combined company may achieve or incur as a result of the acquisition. You should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies been combined during the periods presented. Further, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the combined company. The pro forma adjustments in the unaudited pro forma condensed combined balance sheet as of December31, 2024 and statement of operations for the twelve months ended December31, 2024 are as follows: (A)To record net proceeds of $475,000 in connection sale of 161,290 NLS Common Shares at a purchase price of $3.10 per share on January9, 2025 pursuant to the securities purchase agreement with an accredited investor, dated December4, 2024; (B)To record gross proceeds of $178,699 received in January 2025 related to exercise of warrants for a total of 76,847 NLS Common Shares in connection with the securities purchase agreement with certain accredited investors, dated October9, 2024, and pre -fundedwarrants provided to certain institutional investors upon execution of warrant amendment agreements; (C)To record net proceeds of $2,875,000 in connection with issuance of 1,249,904 preferred shares of NLS, CHF 0.03 par value per share (“Preferred Shares”), with a conversion price of $1.65 per share, 568,278 preferred participation certificates (“PPCs”), as well as warrants to purchase 1,181,818 NLS Common Shares at an exercise price of $1.80 per share, issued in the first closing of a securities purchase agreement entered into with three accredited investors on March27, 2025 (the “March 2025 SPA”), and in the second closing on June26, 2025 (the “June 2025 SPA”); (D)Adjustment to remove $104,963 of interest expenses related to loans converted at closing as noted above as if Merger took place January1, 2024; (E)Adjustment to record additional non -